Phys Clinical Cases · haematological
Myeloproliferative Neoplasms — DCE Clinical Case
DCE long-case and short-case station for Myeloproliferative Neoplasms.
On this page & tools
Target exams
Myeloproliferative Neoplasms — Clinical Case
DCE Long Case
Patient brief
Patient: A middle-aged or older adult with multimorbidity and a presentation centred on Myeloproliferative Neoplasms. [1]
Presenting complaint: Subacute or acute symptoms referable to Myeloproliferative Neoplasms, with enough detail to force prioritisation. [1] [2]
Past history: Common cardiometabolic and organ comorbidities that interact with the plan. [2]
Medications: A polypharmacy list that includes at least one interaction or dosing issue. [2]
Examination: Key positives and critical negatives for dangerous differentials. [1]
Investigations: A small set of results that change management. [1] [2]
Tasks
- Present a prioritised problem list. [1]
- Defend investigations and immediate therapy. [1] [2]
- Provide safety-net and follow-up advice. [2]
Model discussion points
- Working diagnosis and acuity. [1]
- Differentials and discriminators. [2]
- Treatment sequence and monitoring. [1] [2] [3]
- Multimorbidity and communication. [2]
Short case
Focused examination or counselling station linked to Myeloproliferative Neoplasms, with one interpretation task and one shared-decision point. [1] [2]
References
- [1]Rivière E, Guy A, Mansier O, Mediavilla C, et al. Autoimmunity and peginterferon therapy for polycythemia vera Hemasphere, 2026.PMID 42465525
- [2]Hu LJ, Yang WY [Progress in the study of polycythemia vera in children] Zhongguo Dang Dai Er Ke Za Zhi, 2026.PMID 42457335
- [3]Gašljević G, Dora P, Grčar-Kuzmanov B, Urdih T, et al. ARAF mutated langerhans cell histiocytosis developed on the background of ARAF/JAK2 mutated polycythaemia vera: evidence of branching evolution from the same progenitor cell. A case report and literature review Ann Hematol, 2026.PMID 42448959
- [4]Gerds AT, Gotlib J, Abdelmessieh P, Ali H, et al. NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026 J Natl Compr Canc Netw, 2026.PMID 42425157
- [5]Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association [Chinese guidelines on the diagnosis and treatment of adult essential thrombocythemia (2026)] Zhonghua Xue Ye Xue Za Zhi, 2026.PMID 42409729
- [6]Leiva O, Liu OC, Ferrante M, Katsadouros VP, et al. Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know Semin Hematol, 2026.PMID 42243010
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922